It's not for free, though low enough to where no biotech company would make a profit on new therapies at the current R&D spend if the US paid the same rates that everyone else is paying today. This goes for firms on any continent, and a large part of why FDA approval is such a big deal for the international medical enterprise.

We could trade reduced innovation for lower prices, but that's a difficult ethical debate to settle given the prevalence of medical suffering from lack of effective therapies.

The solution I personally petition for is looking for ways to make drug development more affordable across the board.

> It's not for free, though low enough to where no biotech company would make a profit on new therapies at the current R&D spend if the US paid the same rates that everyone else is paying today.

Where are all the anti-taxes people on this apparent involuntary charity for the pharmaceutical industry?